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Abstract 
Multiple sclerosis (MS) is an inflammatory neurological condition that primarily affects young adults. 
The incidence is increasing. Most people with MS initially present with a clinically isolated syndrome; 
which is an initial subacute neurological deficit otherwise known as a relapse. Most are subsequently 
diagnosed with relapsing–remitting MS, the most common form of the disease. Some develop 
secondary progressive MS; primary progressive MS is the least common form. Treatments are based 
on immunomodulation or immunosuppression. There is an increasing emphasis on aggressive early 
management to prevent long-term disability. Increased awareness and knowledge among practising 











● Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system, which 
leads to disability in young adults 
● Environmental risk factors such as smoking, obesity, low vitamin D, low ultraviolet B 
exposure and previous infection with Epstein–Barr virus may significantly increase its risk  
● Pathologically, MS is characterized by the presence of demyelinating plaques 
● Corticosteroids are used to treat relapses, but they do not change the natural history of the 
disease 
● All women presenting with MS should have regular conversations about family planning and 







Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS). It is the most 
common cause of non-traumatic disability in young adults in the UK. MS is thought of as an organ-
specific autoimmune disorder affecting the CNS. It most commonly presents in early adulthood and, 
as with many other autoimmune diseases, is three times more common in women.  
 
Incidence and prevalence, UK and worldwide 
MS affects 2.2 million people worldwide. Approximately 130,000 people across the UK are affected, 
with 6700 being diagnosed each year.  
 
Epidemiology and aetiology 
Several factors appear to play a significant role in an individual's risk of developing MS, including 
polygenic susceptibility as well as Epstein–Barr virus (EBV) seropositivity, low vitamin D levels, 
smoking, obesity and low ultraviolet (UV)B exposure. These combine to significantly increase the risk 
of MS, although individuals may still develop MS in the absence of any known risk factors.  
EBV seropositivity is strongly associated with MS. Late infection with EBV resulting in 
infectious mononucleosis doubles the risk of developing MS. Migration studies illustrate the effect of 
environmental risk factors, with children of migrants to Europe (i.e. second-generation migrants) 
being at high risk. The risk in first-generation migrants appears to depend on the age of migration. 
The latitudinal effect of MS – a greater prevalence in countries further from the equator – correlates 
with vitamin D levels and UVB exposure.  
Family members of MS patients have an increased risk compared with the general 
population. Individuals heterozygote for HLA-DRB1*1501 have an odds ratio (OR) of around 3, and 
homozygous individuals an odds ratio of >6. Over 100 common genetic variants (single-nucleotide 
polymorphisms) have been identified in genome-wide association studies (GWASs) as contributing to 
overall MS risk, although the risk conferred by each individual variant is low (OR approximately 1.1). 
 
Course of the disease 
MS commonly initially presents as clinically isolated syndrome (CIS), the first clinical attack caused by 
focal demyelination, alternatively termed a first clinical relapse. It is possible to diagnose at least 
some patients presenting with CIS with MS at the time of initial presentation – those with multiple 
lesions on magnetic resonance imaging (MRI) and positive cerebrospinal fluid (CSF) oligoclonal bands 
(OCBs) meet the 2017 revisions of the diagnostic criteria. This is based on the high probability of 
these individuals having a second attack. New lesions on sequential MRI (generally accepted as 3 or 
more months apart) can be used as evidence of dissemination in both time and space even in the 
absence of a second clinical attack.  
Patients undergoing MRI for an unrelated reason (e.g. headache) who are found to have 
lesions suggestive of demyelination may be diagnosed with radiologically isolated syndrome (RIS). 
The rates of progression from RIS to CIS or MS remain unclear as they depend on a number of 
factors including case definition and duration of follow-up; however, a significant proportion of 
individuals will develop clinically apparent disease.  
Around 85% of patients have relapsing–remitting MS and experience clinical relapses 
followed by varying degrees of recovery. Of these patients, 50% enter a progressive phase, known as 
secondary progressive MS. Approximately 15% of patients have a clinical course that is progressive 
from the outset without relapses, known as primary progressive MS.  
The nomenclature used to describe these different phases of MS is useful for categorizing 
the disease course but is thought to reflect a continuum within the disease rather than separate 
entities. Disability in MS is measured using the Expanded Disability Status Scale (Figure 1). 
 
Pathogenesis and physiological mechanisms 
MS is characterized pathologically by the presence of demyelinating plaques. These inflammatory 
lesions are caused by CNS invasion of inflammatory cells such as macrophages, CD8 T cells and, to a 
lesser extent, B cells and plasma cells.1 This leads to disruption of myelin and axonal damage, 
causing delay or loss of neuronal signalling, which results in the disability seen clinically. Lesions 
found in relapsing–remitting disease appear to have greater lymphocytic inflammation, while in 
progressive MS, B lymphocytes and plasma cells form a greater proportion of the inflammatory 
infiltrate. As the disease progresses, axons and neurones are affected, leading to progressive, 
gradual neuroaxonal deterioration and resulting brain atrophy. It seems likely that this neuroaxonal 
loss starts early in the disease course, and it may have a different underlying aetiology from the 
inflammation visible on MRI.  
 
Diagnosing MS 
Diagnosis can be challenging because of the clinical and radiological heterogeneity found in MS. A 
summary of the most recent diagnostic guidelines is given in Table 1. When assessing a patient who 
might have MS, the first important step is identifying a clinical syndrome suggestive of MS. The 
symptoms and signs found usually depend on and correspond to the location of the lesion. Optic 
neuritis, brainstem syndromes such as internuclear ophthalmoplegia, cerebellar syndromes and 
transverse myelitis are considered typical, and should prompt further investigation.1 Presentations 
involving higher cognitive function, hemiparesis or psychiatric illness are rare. 
 
Key examination findings 
Clinical signs that are often found in MS patients include the following: a relative afferent pupillary 
defect caused by optic nerve involvement; optic disc pallor secondary to previous optic neuritis; 
internuclear ophthalmoplegia; cerebellar ataxia; and signs suggestive of spinal cord involvement 
including spastic paraparesis, bladder dysfunction and sensory ataxia. 
 
Investigations 
Serology: initial blood tests should include testing for vitamin B12 and folate concentrations, 
antinuclear antibody, HIV, syphilis and thyroid function. Depending on the clinical presentation, it is 
important to consider other blood tests, as detailed in Table 2.  
 
Cerebral spinal fluid: patients with suspected MS should have a lumbar puncture to check for OCBs 
unique to the CSF (i.e. not present in paired serum), which are present in 90% of MS patients. Rarely, 
OCBs are not present early in the disease course. The presence of OCBs can be used to show 
dissemination in time as part of the McDonald criteria. Raised CSF neurofilament levels can provide 
additional support for the diagnosis.  
 
Imaging: MRI of the brain and spinal cord is essential to confirm lesions in keeping with MS and to 
rule out other possible diagnoses. Active lesions enhance with gadolinium contrast, and 
asymptomatic historical lesions may also be noted. Characteristic findings are listed in Table 2 and 
noted in Figure 2. 
 
Electrophysiology: delayed conduction in visual, auditory and sensory evoked potentials, in addition 
to slowed central motor conduction time, can also help to provide evidence for dissemination in 
space in certain cases. 
 
MS mimics 
Table 3 highlights important differential diagnoses. Red flags for MS include bilateral or severe optic 
neuritis, in addition to fever or intractable vomiting; these are more common in neuromyelitis optica 
(NMO, Devic’s disease). Sarcoidosis, NMO associated with aquaporin (AQ4) antibodies, anti-myelin 
oligodendrocyte glycoprotein (MOG)-associated myelitis, tumours, paraneoplastic disorders and 
systemic rheumatological disease can present with transverse myelitis. Fever and high CSF 
pleocytosis in the presence of a transverse myelitis or optic neuritis should lead to investigations for 
another inflammatory cause or infectious process. Involvement of multiple cranial nerves may be 
more typical of neurosarcoid, particularly in the context of leptomeningeal enhancement on MRI. 
Systemic symptoms such as weight loss, night sweats, poor appetite and lethargy should prompt a 
search for an underlying malignancy, while features such as joint pain, rash and lethargy can point to 
a rheumatological cause.3 
Management  
Acute relapse 
Relapses are defined as an acute episode of neurological decline lasting >24 hours. There should be 
no other explanation or evidence of ‘pseudorelapse’ (a deterioration in neurological symptoms not 
caused by new demyelination) triggered by infection. Mild sensory symptoms occurring in isolation 
are usually not treated unless they cause significant distress. Most patients presenting with a relapse 
require MRI, in order to aid decision-making around treatment and to provide a baseline for future 
MRI studies.  
Oral treatment for relapses includes 500 mg of methylprednisolone per day for 5 days. 
Current evidence suggests that there is no difference in medium and long-term outcomes between 
patients given oral or intravenous steroids. However, if patients present with severe relapses, have 
diabetes mellitus or a history of depression or mania, or treatment with oral corticosteroids has 
failed, they may require admission for intravenous methylprednisolone. This is usually given at a 
dose of 1 g/day for 3 days. 
 
Symptomatic treatment 
Symptoms in MS that result from CNS dysfunction include fatigue, depression, cognitive impairment, 
spasticity, sexual dysfunction, paroxysmal symptoms such as trigeminal neuralgia and temperature 
dysregulation. Fatigue affects approximately 80% of patients with MS. Management of fatigue 
includes limiting sedating medicines, ruling out co-morbid depression, addressing obstructive sleep 
apnoea and in some cases giving a prescribed exercise regime.  
Depression occurs in 30% of MS patients and should be screened for at annual reviews. 
Cognitive behavioural therapy and selective serotonin reuptake inhibitors or serotonin–
noradrenaline (norepinephrine) reuptake inhibitors have been shown to improve symptoms. MS-
specific symptomatic therapies include Sativex (an oral cannabis extract) for spasticity and 
fampridine (Fampyra, dalfampridine) for walking, however NHS prescribing of these is limited. 
 
Disease-modifying treatment (DMT) 
An emerging concept in MS therapy is ‘NEDA’, or ‘no evidence of disease activity’, as a treatment 
target for people with MS. This new description has encouraged the earlier use of highly effective 
treatments to prevent subclinical progression of the disease and associated long-term disability. 
NEDA describes a state in which a patient is no longer experiencing relapses or disability progression 
(NEDA 1 and 2, respectively) and does not have any new lesions on MRI (NEDA 3), brain atrophy 
(NEDA 4) or CSF biomarkers such as neurofilaments (NEDA 5).4 
There are now 12 different types of DMT licensed for people with MS, with several in 
development or awaiting regulatory approval. These therapies target the immune system in 
different ways. Interferon-β preparations, glatiramer acetate and teriflunomide are 
immunomodulatory, while natalizumab, fingolimod and ocrelizumab are immunosuppressant. A new 
therapeutic approach has sought to introduce the early use of immune reconstitution therapies, 
such as cladribine, alemtuzumab and haemopoietic stem cell therapy, to provide long-term efficacy 
with interval treatment. 
Table 4 lists DMTs that are currently licensed in the UK (with haemopoietic stem cell therapy 
available via specific regional referral pathways). With more aggressive therapies, there are in 
general greater risks, which can be affected by individual co-morbidities. Natalizumab (Tysabri) has 
been associated with an increased risk of progressive multifocal leukoencephalopathy (PML), a 
subacute neurological condition caused by JC virus infection and more commonly associated with 
HIV/AIDS and other causes of chronic immunosuppression. 
 
Implications in pregnancy 
The peak incidence of MS is in women of childbearing age. Considerations around the management 
of MS in pregnancy are therefore highly important. Recent guidelines have advised that women with 
MS should not defer DMT because they wish to have children in later life, and they should be 
reassured that pregnancy will not increase their risk of disability. Women with MS should be 
encouraged to discuss family planning with their MS team before trying to conceive as DMTs have 
different safety profiles in pregnancy.  
Glatiramer acetate and interferon-β can be continued in pregnancy and while breastfeeding. 
There is increasing evidence supporting the cautious use of natalizumab during (at least) early 
pregnancy – stopping this medication before pregnancy has been associated with significant relapses 
that may lead to sustained disability. A washout period of 4 months after alemtuzumab, 6 months 
after cladribine and 12 months after ocrelizumab should be adhered to before conception.  
The Medicines and Healthcare Products Regulatory Agency has issued a warning regarding 
fingolimod and an association with teratogenicity – women taking this medication must have a 
negative pregnancy test before starting the medication, use adequate contraceptive methods and 
have at least a 3-month washout before trying to conceive. Teriflunomide is teratogenic in animals, 
and there are relatively few data on human pregnancies. Teriflunomide can be detected in the 
seminal fluid of men taking the drug, and the implications of this for exposure of the female partner 
should be considered in men with MS who want to start a family.  
Dimethyl fumarate has a short washout period, and there is currently no signal for 
teratogenicity associated with fetal exposure. However, it is not recommended for women with MS 
during pregnancy or breastfeeding.5 It is important for MS clinicians to be informed as soon as 
possible in the event of an unplanned pregnancy. Clinicians should be aware that corticosteroids and 
plasma exchange can be still be used for relapses in pregnancy, that MRI is not contraindicated but 




Figure 1. Expanded Disability Status Scale.  







Figure 2. White matter lesions in a distribution typical of MS.  
MRI showing periventricular lesions (red arrow) with Dawson’s fingers (yellow) which are 
ovoid lesions perpendicular to the ventricle. Multiple brainstem and cerebellar lesions are 
shown in the MRI slice on the right. 





Summary of the 2017 McDonald Criteria for RRMS  
 
Dissemination in space  •Objective clinical evidence of 2 lesions or objective clinical 
evidence of 1 lesion with historical evidence of a prior attack 
involving a different CNS site or 
•≥1 T2 lesion in at least 2 of 4 of MS-typical areas of the CNS 
(infratentorial, juxtacortical, periventricular, spinal cord) 
Dissemination in time •≥2 attacks separated by at least 1 month or 
•Simultaneous presence of asymptomatic gadolinium-
enhancing and non-enhancing lesions at any time or 
•A new T2 or gadolinium-enhancing lesion on follow-up MRI 
irrespective of timing or 
•Presence of (2 or more) OCBs in CSF  
Table 1  




Investigations required in a patient presenting with CIS 
Baseline serology Vitamin B12, folate, antinuclear antibody, antineutrophil cytoplasmic 
antibodies, thyroid function, HIV, syphilis 
Serology depending 
on presentation 
Anti-aquaporin 4 (AQ4) antibody, anti-myelin oligodendrocyte glycoprotein 
(MOG) antibody – both for neuromyelitis optica 
Erythrocyte sedimentation rate, rheumatoid factor, complement 
Anti-double-stranded DNA, anti-cardiolipin, anti-phospholipid, Lyme 
disease – IgG/IgM 
Human T-cell lymphocytic virus 1 and 2 serology 
Lumbar puncture Presence of unmatched OCBs 
MRI brain ± spinal 
cord ± gadolinium 
New lesions enhance with gadolinium (for up to 1 month) 
 
Typical brain lesions  
•Periventricular Dawson’s fingers (ovoid lesions perpendicular to 
ventricles) 
•Involvement of corpus callosum 
•Infratentorial lesions: peripheral lesions in the brainstem and cerebellum 
•Juxtacortical lesions (those touching the cortex) 
·  
· Spinal cord lesions 
· •Less than two vertebral segments in height 
· •Lesions are small and peripherally located 
Visual and auditory 
sensory-evoked 
potentials  
Delayed conduction times reflect areas of demyelination 





Differential diagnosis of relapsing and progressive MS 
Optic neuritis Isolated 
brainstem 
syndrome 










































































Toxic/nutritional Toxic/nutritional  Toxic/nutritional/meta
bolic 
• Vitamin B12 
deficiency 
• Nitrous oxide 
toxicity 
• Copper deficiency 
Susac’s syndrome Infectious causes 
• HIV 














• Myasthenia gravis 
  
Table 3 
ADEM, acute disseminated encephalomyelitis; CADASIL, cerebral autosomal dominant arteriopathy 
with subcortical infarcts and leucoencephalopathy; CLIPPER, chronic lymphocytic inflammation with 
pontine perivascular enhancement responsive to steroids; TIA, transient ischaemic attack. 
  
 
DMTs currently licensed or under investigation* in the UK 
 Trade name(s) Administration Main adverse effects 
First-line injectables    





according to brand  
Injection site, flu-like symptoms, 
abnormal LFTs, leucopenia 
PEG-IFN-β 1a Plegridy 125 micrograms s.c. 
2 weekly 
Injection site, flu-like symptoms, 
abnormal LFTs, leucopenia 




20 mg s.c. daily or 
40 mg s.c. three 
times a week 
(Copaxone only) 




   






120mg bd for first 2 
weeks, 
maintenance dose 
240 mg twice daily 
p.o. 
Flushing, gastrointestinal 
symptoms, lymhopenia, abnormal 
LFTS, proteinuria, PML 
Teriflunomide Aubagio 14 mg daily p.o. Hair thinning, gastrointestinal 




   
Fingolimod Gilenya 0.5 mg daily p.o. Bradycardia (first dose), 
hypertension, bronchospasm, 
lymphopenia, abnormal LFTs, 
infections, basal cell cancer, 
macular oedema, opportunistic 
infections (PML, cryptococcosis) 
Intravenous 
immunosuppressive  
   
Natalizumab Tysabri 300 mg i.v. 4-
weekly 
Infusion reactions, PML 
Ocrelizumab Ocrevus Initially 300 mg i.v., 
second dose 2 
weeks later 300 mg 
i.v., subsequently 





   
Alemtuzumab Lemtrada Year 1: 12 mg i.v. × 
5 days 
Year 2: 12 mg i.v. × 
3 days 
Infusion reactions, opportunistic 
and other infections, leucopenia, 
secondary autoimmunity (thyroid, 
ITP, renal) 
Cladribine Mavenclad Total dose of 3.5 
mg/kg over 2 years 
(given as 2 courses 
1 year apart)  
Lymphopenia, infections 




 According to 
protocols 
Adverse events as for those related 
to induction chemotherapy 
Table 4 
Bold type indicates serious adverse effects to be aware of. 
ITP, idiopathic thrombocytopenic purpura; i.v., intravenously; LFT, liver function test; p.o., orally; 
s.c., subcutaneously.  
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To test your knowledge based on the article you have just read, please complete the questions below. 
The answers can be found at the end of the issue or online here. 
 
QUESTION 1 
A 27-year-old woman presented with a 2-day history of diplopia and blurring of vision on looking to 
the left. She had had some numbness in her right foot 6 months previously that had resolved before 
she sought medical attention. 
On clinical examination, when asked to look to the left, she had failure of adduction to the left and 
horizontal nystagmus in the right eye on abduction.  
 
What is the clinical sign? 
 
A. Intranuclear ophthalmoplegia of the left eye 
B. Intranuclear ophthalmoplegia of the right eye 
C. Relative afferent pupillary defect of the left eye 
D. Relative afferent pupillary defect of the right eye  
E. Optic neuritis of the left eye 
 
Correct answer: A. 
Intranuclear ophthalmoplegia is a disorder of eye movement caused by damage to the medial 
longitudinal fasciculus, resulting in ipsilateral adduction failure with horizontal nystagmus in the 
unaffected eye on abduction. It results in blurring and double vision. A relative afferent pupillary 
defect is a condition in which the affected pupil becomes dilated when assessing direct response 
using the swinging flashlight test. Optic neuritis presents with painful visual loss in the affected eye 




A 33-year-old woman presented with weakness of both legs (power 4/5), associated with tingling 
and numbness to the level of the umbilicus. She was finding it difficult to walk, but could manage to 
mobilise independently. She was known to have multiple sclerosis and was 20/40 weeks’ pregnant. 
After discussion with her multiple sclerosis consultant, she had stopped taking her disease-modifying 
treatment prior to pregnancy. She had experienced similar symptoms during previous relapses of 
her multiple sclerosis. She had no  dysuria or cough, and her inflammatory markers were normal.  
 
What is the most appropriate management plan? 
 
A. Urine dipstick, discuss with neurology team, consider MRI of the brain and spine either during or 
shortly after pregnancy, consider oral corticosteroids for management of acute relapse 
B. CT of the brain and spine, start oral corticosteroids 
C. Treatment with methylprednisolone intravenously 
D. Restart disease-modifying treatment  
E. Manage conservatively, refer to the multiple sclerosis specialist nurse 
 
Correct answer: A. 
Pregnant MS patients having a clinical relapse should be discussed with their MS team, or the 
neurology team if their MS team is not available. All people with MS having a possible relapse should 
have a urine dip performed, as UTI is a common cause of pseudorelapse. MRI is not contraindicated 
in pregnancy, but discussions about investigations and treatment of pregnant patients should be led 
by the neurology team. MRI is the investigation of choice in all MS patients presenting with 
symptoms suggestive of a relapse with motor signs, and should be completed prior to initiating any 
therapy. Oral steroids for relapses impacting on function can be considered during pregnancy, but 
patients need to be carefully counselled. CT is not generally a useful investigation for MS relapses. 
Discussion with the neurology team is also important so that appropriate management and timely 




A 55-year-old man presented with his partner who reported that, over the past 3 months, she had 
been concerned that he had not been himself, had been irritable and had angered easily, which was 
unusual for him. In addition, he had seemed to have been a little clumsy over the previous week. He 
had previously been found to have relapsing–remitting multiple sclerosis but had been relatively 
stable since starting natalizumab. The last documented relapse had been a year before.  
 
What is the appropriate next step in management? 
 
A. Refer to psychiatry, consider starting antidepressants 
B. Screen for urine infection and start corticosteroids, to attend for next natalizumab infusion 
as planned 
C. Manage conservatively, review in the clinic in 4 months, with a multiple sclerosis specialist 
nurse review if needed 
D. Admission for John Cunningham (JC) virus serology, urgent lumbar puncture for JCV viral 
load, MRI to rule out progressive multifocal leucoencephalopathy (PML). Withold 
natalizumab until above investigations performed.  
E. Reassure his partner and refer him to outpatient physiotherapy. 
 
Correct answer: D. 
 
This patient has been treated with Natalizumab, a side effect of which can be the development of 
progressive multifocal leukoencephalopathy (PML) a rare but potentially fatal complication 
caused by reactivation of the JC virus. It usually develops over weeks to months and presents 
with features such as clumsiness, weakness, speech, visual and personality changes. It may 
mimic a relapse; however MRI and lumbar puncture should be performed as a matter of 
urgency. Early cessation of natalizumab and consideration of adjunct treatment is associated 
with improved outcomes, and so natalizumab should not be continued until PML is excluded. 
 
